pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cagrisema · news · pharmadog
← back to Cagrisema
News mentioning Cagrisema
20
stories
5d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
5d
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
5d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
13d
Novo talks up drug launches in effort to win back investors
biopharma dive
13d
Novo offers low-dose CagriSema data as approval decision looms
endpoints
14d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
14d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
Aug 19, 26
Amylin design debate heats up as Lilly's crucial mid-stage weight loss data near
endpoints
Aug 19, 26
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
Aug 7, 26
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
fiercebiotech
Aug 5, 26
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
Aug 5, 26
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
Aug 5, 26
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
Aug 5, 26
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
Aug 4, 26
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
biospace
Jul 31, 26
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
Jul 29, 26
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
Jul 29, 26
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
May 6, 26
Novo hikes guidance on Wegovy pill’s fast sales start
biopharma dive
